Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1

Conditions

Venous Thromboembolism 3Neoplasms 3Venous Thrombosis 2Thrombosis 2Pancreatic Neoplasms 2Thromboembolism 1Stomach Neoplasms 1Pulmonary Embolism 1Ovarian Neoplasms 1Obesity 1Multiple Myeloma 1Gliosarcoma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Embolism and Thrombosis 1Embolism 1Duodenal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 295Fluorouracil 82Oxaliplatin 81130-nm albumin-bound paclitaxel 68Capecitabine 60Leucovorin 56Albumin-Bound Paclitaxel 54Radiotherapy 51Irinotecan 44Taxes 37Cisplatin 36Erlotinib Hydrochloride 34Radiosurgery 33pembrolizumab 29Docetaxel 27S 1 (combination) 26Bevacizumab 23folfirinox 22Nivolumab 21Magnetic Resonance Spectroscopy 17Cyclophosphamide 17Cetuximab 17irinotecan sucrosofate 16Radiation 16Drug Therapy 15Surgical Procedures, Operative 14Specimen Handling 11Biopsy 11durvalumab 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Neoplasms × Dalteparin × Clear all
NCT03139487 2020-01-06

PRIORITY

Asan Medical Center

Phase 2 Unknown
176 enrolled
GastrointestinalSarcoma

Biliary Tract Neoplasms, Duodenal Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Gastrointestinal Stromal Tumors

NCT00462852 2013-08-12

Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
120 enrolled
Gastrointestinal

Pancreatic Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡